Core Viewpoint - The Hang Seng Hong Kong Stock Connect Innovative Drug Index has seen a 0.3% increase, with significant gains in individual stocks, reflecting a positive trend in the innovative pharmaceutical sector driven by government policies and increasing demand for new drugs [1] Group 1: Market Performance - The Hang Seng Hong Kong Stock Connect Innovative Drug Index rose by 0.3% [1] - Notable stock performances include BGI Genomics rising over 7%, Tonghua Dongbao Pharmaceutical increasing over 4%, and Innovent Biologics up over 2% [1] - The trading volume for the Hong Kong Stock Connect Innovative Drug ETF, E Fund (159316), reached approximately 500 million yuan [1] Group 2: Government Policy - The "Guangzhou Plan for Accelerating the Construction of a Strong Advanced Manufacturing City (2024-2035)" was recently issued, emphasizing the acceleration of innovative drug strategic layout [1] - The plan focuses on the development of monoclonal antibodies, vaccines, blood products, and diagnostic reagents in the biopharmaceutical sector [1] - Other cities such as Beijing, Shanghai, Chongqing, and Xi'an have also introduced policies to promote high-quality development in the innovative drug industry [1] Group 3: Industry Outlook - Huachuang Securities believes that the pharmaceutical industry is reaching new heights due to the continuous demand for medical solutions and unmet needs [1] - Pharmaceutical companies are increasingly investing in research and development to meet these demands [1] - China has become a significant player in global innovative drug research and development, with a continuous rise in overseas licensing activity [1] - The industry is entering a revenue era driven by innovation [1] Group 4: Investment Opportunities - The Hang Seng Hong Kong Stock Connect Innovative Drug Index is the first index with a "purity" of 100% focused on innovative drugs, targeting leading companies in the Hong Kong stock market [1] - The E Fund (159316) is currently the only product tracking this index, providing investors with a streamlined way to capitalize on investment opportunities in this sector [1]

Group 1 - The Hang Seng Index (HSI) rose by 27.8% in 2025, marking its best performance since 2017, following a 17.7% increase in 2024 [1] - The rise in the HSI was driven by record capital inflows from the Hong Kong Stock Connect, optimism about the future of artificial intelligence, and interest rate cuts [1] - The HSI outperformed two other flagship indices: the Hang Seng China Enterprises Index (up 22.3%) and the Hang Seng Tech Index (up 23.5%) [1] Group 2 - The Hang Seng Composite Index (HSCI) increased by 31.0% in 2025, with mid-cap stocks leading the gains at 31.6%, followed by large-cap stocks at 30.8% and small-cap stocks at 28.8% [2] - Among industry indices in the HSCI, the materials sector had the best performance, rising by 161.3%, while utilities had the worst performance with a 5.7% increase [2] - The Hang Seng High Dividend Yield 30 Index led the high dividend indices with a rise of 38.1% in 2025 [2] Group 3 - The Hang Seng Climate Change 1.5°C Target Index performed well, with an annual increase of 31.2% [3]

Core Viewpoint - The Hong Kong innovative drug sector is experiencing a significant rise, driven by supportive government policies and a focus on high-quality development in the pharmaceutical industry [1][2]. Group 1: Market Performance - The Hang Seng Hong Kong Stock Connect Innovative Drug Index rose by 2.0% as of 11:05 AM, with notable gains in stocks such as InnoCare Pharma-B, which increased by over 7%, and Lepu Biopharma-B, Innovent Biologics, and 3SBio, each rising by over 4% [1]. - The Hang Seng Innovative Drug ETF (159316) recorded a trading volume of nearly 400 million yuan [1]. Group 2: Policy Support - Xi'an has released the "Implementation Plan for Promoting the Capacity Enhancement of the Biopharmaceutical Industry (2025-2027)," aiming to achieve breakthroughs in key drug development technologies in areas such as stem cell drugs, peptide drugs, liver-targeted innovative drugs, and anesthetics [1]. - Various regions, including Beijing, Shanghai, Chongqing, and Sichuan, have introduced policies this year to promote high-quality development in the innovative drug sector [1]. Group 3: Industry Outlook - Changjiang Securities notes that the pharmaceutical industry is experiencing a policy cyclical trend, with comprehensive support policies for the innovative drug industry being gradually implemented [1]. - The industry is entering a new cycle of policy support, with a focus on "hard innovation" assets and those with strong overseas potential [1].

Core Viewpoint - The pharmaceutical industry is experiencing fluctuations, with A-share pharmaceutical sector showing collective low-level volatility, while Hong Kong's pharmaceutical sector is seeing wide fluctuations and slight declines, particularly in the innovative drug sub-sector which is showing strength [1] Group 1: Market Performance - The Hang Seng Hong Kong Stock Connect Innovative Drug Index rose by 0.9%, achieving a "four consecutive days of gains" [1] - The CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index fell by 0.01% [1] - The CSI Biotech Theme Index decreased by 0.6%, while both the CSI Innovative Drug Industry Index and the CSI 300 Pharmaceutical and Health Index dropped by 0.7% [1] Group 2: Industry Insights - According to Citic Securities, Chinese pharmaceutical companies account for approximately 30% of the global business development (BD) transaction volume [1] - The characteristics of innovative drug research and development in China are described as "fast, good, economical," making it a significant source for overseas pharmaceutical companies' product introductions [1] - Domestic pharmaceutical companies are transitioning from being demand-side players in innovative drug projects to becoming providers, with BD income becoming an important source of revenue expansion [1]

Core Insights - The Chinese pharmaceutical industry is entering a critical phase characterized by "innovation realization and global expansion," supported by population and domestic demand, as well as comprehensive manufacturing capabilities [1] - Companies are actively exploring diversified overseas pathways, with a focus on innovation commercialization, global breakthroughs, policy optimization, and opportunities for industry mergers and acquisitions by 2026 [1] Index Performance - The Hang Seng Hong Kong Stock Connect Innovative Drug Index rose by 0.9% [1] - The China Securities Hong Kong Stock Connect Medical and Health Comprehensive Index increased by 1.0% [1] - The China Securities Innovative Drug Industry Index decreased by 0.2% [2] - The China Securities Biotechnology Theme Index fell by 0.6% [1] - The CSI 300 Medical and Health Index declined by 0.7% [1] ETF Details - The Hang Seng Innovative Drug ETF tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Index, which focuses on innovative drug companies in Hong Kong [2] - The index consists of no more than 40 stocks involved in innovative drug research, development, and production, with a rolling P/E ratio of 58.2 times [2] - The China Securities Hong Kong Stock Connect Medical and Health Comprehensive Index includes 50 stocks from the medical device, biopharmaceutical, and chemical drug sectors, with a rolling P/E ratio of 28.3 times [2] - The China Securities Innovative Drug Industry Index focuses on A-share innovative drug leaders, comprising no more than 50 stocks, with a rolling P/E ratio of 49.9 times [2] - The China Securities Biotechnology Theme Index includes up to 50 stocks in gene diagnostics, biopharmaceuticals, and blood products, with a rolling P/E ratio of 54.8 times [3] - The CSI 300 Medical and Health Index covers companies in the medical and health sector, with a rolling P/E ratio of 30.7 times [3]

Group 1 - The core viewpoint is that the recent meeting between the US and China leaders has positively impacted the market sentiment towards innovative drugs, leading to significant gains in related stocks and ETFs [1][2] - The Hang Seng Innovative Drug ETF (159316) saw a net inflow of over 1.7 billion yuan in the past 20 days, indicating a clear trend of bottom-fishing by investors [2] - The Hang Seng Innovative Drug Index, which excludes CXO companies, focuses on core enterprises in the innovative drug industry, providing investors with a convenient tool to invest in leading innovative drug companies in Hong Kong [2] Group 2 - The industry fundamentals indicate that 2025 will be a critical year for Chinese innovative drugs going global, with expected patent licensing transaction amounts exceeding 100 billion USD, a 170% year-on-year increase [1] - China has become a significant contributor to the global innovative drug industry, with the proportion of patents acquired by the US from Chinese companies rising from 5% in 2019 to 24% [1]

Core Viewpoint - The innovative drug industry trend remains unchanged, with sufficient adjustments made currently, and it is expected that innovative drugs will rise again after the third quarter reports [1] Group 1: Industry Trends - The CXO sector is performing well, benefiting from potential performance catalysts and high prosperity, with the overseas CXO industry entering a phase of accelerated recovery [1] - There is a clear recovery trend in macro-level BD transactions and mergers and acquisitions, while micro-level new molecular businesses maintain high prosperity [1] - The medical device sector is experiencing a policy turning point, with stock prices, valuations, and allocations at the bottom, and the fundamentals are expected to improve [1] Group 2: Investment Recommendations - It is recommended to focus on innovative drugs, the innovative drug industry chain (export-oriented CXO), and medical devices as the main lines for medium to long-term investment [1] Group 3: ETF Performance - The Guotai Innovation Drug ETF (589720) focuses on innovative drug companies on the Sci-Tech Innovation Board, tracking 30 representative quality companies in the Shanghai Stock Exchange Sci-Tech Innovation Drug Index, primarily featuring high-growth biotech [1] - Since the "924 market" last year, the Sci-Tech Innovation Drug Index has outperformed the Hang Seng Hong Kong Stock Connect Innovative Drug Index, with respective gains of 117.04% and 109.62% during the market rebound period from September 24, 2024, to September 30, 2025 [1] - The Sci-Tech Innovation Drug Index may help better share the elasticity of the Sci-Tech Innovation Board when market risk appetite rebounds [1]

Core Viewpoint - The Hong Kong innovative drug sector is experiencing a strong performance, with the Hang Seng Innovative Drug Index rising by 1% as of 14:26, indicating positive market sentiment towards Chinese innovative pharmaceutical companies [1] Group 1: Market Performance - The Hang Seng Innovative Drug Index saw a rise of 1%, with notable gains from stocks such as Cloudtop New Drug rising over 5%, and Zai Lab and Four Rings Pharma both increasing over 3% [1] - The Hang Seng Innovative Drug ETF (159316) recorded a net subscription of over 120 million units during the trading session, reflecting strong investor interest [1] Group 2: Industry Developments - At the 2025 European Society for Medical Oncology (ESMO) annual meeting, Chinese innovative drug companies contributed over 440 abstracts, with 32 studies included in the latest breakthrough abstracts, showcasing their research capabilities across multiple cancer types [1] - According to Industrial Securities, the innovative drug sector's favorable conditions are expected to persist, with the "innovation + internationalization" trend remaining a core focus of the pharmaceutical industry [1] Group 3: Investment Opportunities - The innovative drug industry is anticipated to continue receiving policy support, enhancing the global competitiveness of Chinese innovative drugs and ensuring ongoing commercial profitability [1] - The Hang Seng Innovative Drug Index has been designed to exclude CXO, making it the first "pure" innovative drug index with 100% purity, accurately reflecting the overall performance of Chinese innovative drug companies [1] - The Hang Seng Innovative Drug ETF (159316) is currently the only product tracking this index in the market, providing investors with a streamlined way to capitalize on opportunities in the innovative drug sector [1]

Core Insights - The trend of Chinese innovative drugs going global is a long-term development, with limited impact from external environmental changes [1] - In the first half of 2025, there were 72 License-out transactions from China, exceeding half of the total transactions in 2024, with a total transaction value 16% higher than that of 2024 [1] - The number of significant business development (BD) deals from listed companies has decreased, and NewCo format BDs have not met market expectations [1] Industry Performance - The China Science and Technology Innovation Drug ETF (GTJA, 589720) focuses on innovative drug companies on the Sci-Tech Innovation Board, tracking an index of 30 representative high-quality companies [1] - Since the "924 market" rally last year, the Sci-Tech Innovation Drug Index has outperformed the Hang Seng Hong Kong Stock Connect Innovation Drug Index [1] - During the market rebound from September 24, 2024, to October 10, 2025, the Sci-Tech Innovation Drug Index and the Hang Seng Hong Kong Stock Connect Innovation Drug Index increased by 103.5% and 100.5% respectively [1]

Group 1 - The core viewpoint is that there are several promising directions for technology investment, particularly in AI innovation, humanoid robots, and self-controllable technology in the chip sector [1] - AI capital expenditure is still in its early stages and remains largely conceptual, indicating potential for future growth [1] - The active users in the AI field are noteworthy, with a potential shift from free to paid AI services in the future, which could significantly impact company performance and market growth [1] Group 2 - The innovative drug sector has shown significant performance this year, driven by notable advancements in drug development and resulting changes in company earnings [1] - The innovative drug industry has high financing requirements, and the current macroeconomic environment, characterized by relatively loose global monetary policy, presents a favorable opportunity for growth [1] - The valuation of the Hong Kong innovative drug sector has greater room for improvement, making the Hang Seng Hong Kong Stock Connect Innovative Drug Index a point of interest [1]